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Abstract
Background: Vitamin D regulates bone mineral metabolism and skeletal development. Some observational studies
have suggested that prenatal vitamin D deficiency increases the risk of adverse pregnancy and/or birth outcomes;
however, there is scant evidence from controlled trials, leading the World Health Organization to advise against
routine vitamin D supplementation in pregnancy. Importantly, little is known about the effect of maternal vitamin D
status on infant linear growth in communities in South Asia where stunting is highly prevalent and maternal-infant
vitamin D status is commonly suboptimal.
Methods/Design: The Maternal Vitamin D for Infant Growth study is a randomized, placebo-controlled, dose-ranging
trial of maternal vitamin D supplementation during pregnancy and lactation in Dhaka, Bangladesh. The primary aims
are to estimate (1) the effect of maternal prenatal oral vitamin D3 supplementation (4200 IU/wk, 16,800 IU/wk, or 28,000
IU/wk, administered as weekly doses) versus placebo on infant length at 1 year of age and (2) the effect of maternal
postpartum oral vitamin D3 supplementation (28,000 IU/wk) versus placebo on length at 1 year of age among
infants born to women who received vitamin D 28,000 IU/wk during pregnancy. Generally healthy pregnant
women (n = 1300) in the second trimester (17–24 weeks of gestation) are randomized to one of five parallel arms:
placebo 4200 IU/wk, 16,800 IU/wk, or 28,000 IU/wk in the prenatal period and placebo in the postpartum period
or 28,000 IU/wk in the prenatal period and 28,000 IU/wk in the postpartum period. Household- and clinic-based
follow-up of mother-infant pairs is conducted weekly by trained personnel until 26 weeks postpartum and every
3 months thereafter. The primary trial outcome measure is length for age z-score at 1 year of age. Anthropometric
measurements, clinical information, and biological specimens collected at scheduled intervals will enable the
assessment of a range of maternal, perinatal, and infant outcomes.
Discussion: The role of vitamin D in maternal and infant health remains unresolved. This trial is expected to
contribute unique insights into the effects of improving maternal-infant vitamin D status in a low-income setting
where stunting and adverse perinatal outcomes represent significant public health burdens.
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Background
Many low-income countries in Asia have experienced
substantial recent reductions in mortality rates among
children younger than 5 years of age [1]; for example,
Bangladesh has met United Nations Millennium Develop-
ment Goal 4—a two-thirds reduction in child mortality
between 1990 and 2015. However, childhood undernutri-
tion remains a persistent global public health problem [2],
particularly in Sub-Saharan Africa and South Asia [3]. In
Bangladesh, stunting (height or length less than 2 standard
deviations below the standard median for age and sex)
was estimated to affect 51 % of children younger than 5
years of age in 2004, but declined to 43 % in 2007 and to
41 % in 2011 according to national surveys [4].
Fetal and early childhood growth is believed to have a
critical influence on early childhood infectious disease
susceptibility, mortality, and long-term functional and
social outcomes, particularly during the first 1000 days
of pre- and postnatal development [5, 6]. Postnatal linear
growth faltering—an abnormally slow velocity of length/
height gain that may eventually lead to stunting—often
begins early in infancy in low-income settings (i.e.,
within the first 3 months of life [7]), suggesting an im-
portant contribution by prenatal determinants, including
epigenetic and endocrine factors that regulate growth in
the first months of life. However, the causal pathways
implicated in early childhood stunting remain poorly
understood [8, 9].
Vitamin D is a well-established regulator of bone min-
eral metabolism and skeletal development [10]. Children
with severe vitamin D deficiency rickets have secondary
hyperparathyroidism and demineralization of the growing
skeleton, as well as impairment of bone elongation [11].
Vitamin D treatment of affected children leads to an ac-
celeration of linear growth accompanied by resolution of
the hyperparathyroidism [11–13]. Effects of improvements
in vitamin D status on linear growth in infants and chil-
dren without rickets have not been widely studied;
however, in one trial in India, weekly vitamin D supple-
mentation of low birth weight infants reduced the risk of
stunting in adjusted analyses [14]. Vitamin D status is
therefore a logical candidate as a modifiable nutritional
determinant of linear growth in communities where stunt-
ing is prevalent and vitamin D status is commonly sub-
optimal. In South Asia, there is a high prevalence of
biochemical vitamin D deficiency among women and
young infants [15]; in Dhaka, we found that 34 % of preg-
nant women at 26–29 weeks gestation (N = 160) had
serum 25-hydroxyvitamin D (25(OH)D) concentrations
less than 30 nmol/L, and that 64 % had 25(OH)D levels
less than 50 nmol/L [16], a threshold for sufficiency
adopted by the Institute of Medicine (IOM) [17]. In the
absence of maternal vitamin D supplementation, postnatal
infant 25(OH)D concentration was low in the neonatal
period, but gradually increased over the first several
months of life (unpublished observations). Therefore, in
Bangladesh, we have observed that the period of greatest
vulnerability with respect to perinatal vitamin D deficiency
overlaps with a critical period of fetal and early infant
growth. Because maternal vitamin D status is the predom-
inant determinant of fetal and neonatal vitamin D stores
[18], prenatal vitamin D supplementation represents the
optimal approach to testing the effect of improving
maternal-infant vitamin D status on fetal-infant growth
and other health outcomes.
Observational studies of the association between ma-
ternal prenatal vitamin D status and infant anthropom-
etry have yielded conflicting findings [19–23]. The
effects of prenatal vitamin D supplementation on infant
length have not been widely studied in controlled trials.
In a study conducted in the 1970s in London, England,
prenatal vitamin D supplementation reduced the risk of
small for gestational age (SGA) versus control, but there
was no significant effect on birth length [24]; however,
the infants in the vitamin D group had significantly
greater mean length at 1 year of age [25]. We recently
completed a randomized, placebo-controlled, double-
blinded trial of maternal third-trimester vitamin D3 sup-
plementation in Dhaka, in which 160 women were ran-
domized to receive either 35,000 IU/wk or placebo until
delivery. Maternal mean 25(OH)D was significantly
higher at delivery after receiving vitamin D versus pla-
cebo (134 vs. 39 nmol/L; P < 0.001; N = 133). There was
a parallel difference in cord 25(OH)D (103 nmol/L in
vitamin D group vs. 39 nmol/L in placebo group; P <
0.001; N = 132) [16]. Analyses of the effect of prenatal
vitamin D supplementation on infant length among 134
infants followed up to 1 year of age revealed that infants
born to women in the vitamin D group had mean length
for age z-scores (LAZs) at 1 year that were significantly
greater than infants in the placebo group (mean = 0.44
z-score units higher; 95% confidence interval [CI], 0.06–
0.82) [26]. This corresponded to an approximate halving
of the prevalence of stunting (11 % vs. 21 %), which
would constitute a substantial public health benefit. The
effect appeared to be attributable to a significantly accel-
erated increase in mean LAZ from birth to 1 month of
age (change of 0.53 z-score in vitamin D versus 0.19 z-
score in placebo group; P = 0.004) rather than a signifi-
cant difference in birth length [26]. However, some
animal [27] and observational [21, 28] studies have sug-
gested an effect of maternal prenatal vitamin D status on
growth of the fetus.
There has been considerable recent interest in the role
of vitamin D in maternal and infant health outcomes in
low-income settings [29]. Some observational studies
have suggested that antenatal vitamin D deficiency in-
creases the risk of adverse pregnancy and birth outcomes,
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including SGA [30, 31]. However, there is scant evidence
from controlled clinical trials [31, 32], and the World
Health Organization (WHO) recently advised against rou-
tine vitamin D supplementation in pregnancy until further
data become available [33]. Building on our earlier find-
ings of a beneficial effect of prenatal vitamin D supple-
mentation on infant length in a preliminary trial [26], we
are conducting a larger dose-ranging trial of maternal vita-
min D3 supplementation in Dhaka, Bangladesh. The pri-
mary aim is to investigate the effect of maternal vitamin D
supplementation on infant length at 1 year of age, but the
trial also provides an opportunity to study a range of other
potential vitamin D–responsive outcomes.
Methods/Design
The Maternal Vitamin D for Infant Growth (MDIG) trial
is randomized, placebo-controlled, dose-ranging trial of
maternal vitamin D supplementation during pregnancy
and lactation to improve infant linear growth in Dhaka,
Bangladesh (ClinicalTrials.gov identifier NCT01924013).
A detailed trial protocol was developed in accordance
with the SPIRIT guidelines [34] through a collaboration
between the International Centre for Diarrhoeal Disease
Research (ICDDR,B; Dhaka, Bangladesh) and the Hos-
pital for Sick Children (Toronto, ON, Canada) and
with funding from the Bill and Melinda Gates Founda-
tion through its Achieving Healthy Growth platform
(http://gcgh.grandchallenges.org/grantopportunities/
pages/healthygrowth.aspx).
The first participant was enrolled on 18 March 2014;
enrollment is expected to proceed until August 2015;
and planned data collection will continue until 2018.
Objectives
The primary aims of the trial are to estimate (1) the ef-
fect of maternal prenatal oral vitamin D3 supplementa-
tion (4200 IU/wk, 16,800 IU/wk, or 28,000 IU/wk
administered as weekly doses) versus placebo on infant
length at 1 year of age in Dhaka, Bangladesh; and (2) the
effect of maternal postpartum oral vitamin D3 supple-
mentation (28,000 IU/wk) versus placebo on length at 1
year of age among infants born to women who received
vitamin D 28,000 IU/wk during pregnancy. Secondary
anthropometric outcomes include birth size and the
prevalence of SGA, the prevalence of stunting at 1 year
of age, and mean attained LAZ and stunting prevalence
at 2 years of age.
Clinical, biochemical, and microbiological surveil-
lance of enrolled mother-infant pairs will enable a
range of secondary objectives to be addressed, includ-
ing (1) estimation of the effect of maternal vitamin D
supplementation on the incidence of acute respiratory
infections (ARIs) during early infancy; (2) exploration of
the roles of specific hormones, nutrients, environmental
contaminants, and inflammatory markers in the mediation
or modification of the effect of vitamin D on fetal and in-
fant growth, with particular emphasis on the role of the
parathyroid hormone (PTH) system; and (3) investigation
of the role of epigenetic modification of genes involved in
perinatal vitamin D metabolism in infant stunting.
Setting and participants
Recruitment, enrollment, and clinical activities are
based at the Maternal and Child Health Training Insti-
tute (MCHTI), a Bangladeshi national government-
operated facility that provides health care to pregnant
women and children in its referral area in central
Dhaka, Bangladesh. MCHTI has outpatient antenatal
care clinics, a labor and delivery unit, and inpatient
pediatric services. The Dhaka wards and/or unions near
MCHTI that are included in the trial area include Kam-
rangirchar, Azimpur, Lalbag, and Hazaribag. About
three-fourths of the participants are expected to be resi-
dents of Kamrangirchar, a group of urban slums on the
Buriganga River along the periphery of Dhaka city. The
area is densely populated, with a total population of
about 300,000, of whom approximately 265,000 reside
in slum settlements [35]. The literacy rate is approxi-
mately 29 % (compared with the national average of 32
%) and more than 30 % of the residents have monthly
incomes of 5000 taka (about US$60) or less. Income
earners are mainly day laborers (e.g., rickshaw pullers),
and many men work in local tanneries or operate small
businesses. However, the socioeconomic status of resi-
dents varies, owing to the presence of some universities
and government offices in the area.
The MDIG trial is an efficacy study designed to test a
specific biological mechanism implicated in fetal and
infant growth. We therefore established a detailed set
of eligibility criteria that will optimize the internal val-
idity of the trial by minimizing the number of with-
drawals due to loss to follow-up or serious adverse
events, acknowledging that this may theoretically re-
duce the generalizability of the findings. Among women
presenting to MCHTI for antenatal care, participant eli-
gibility is based on the following inclusion criteria: age
18 years and older, intention to reside in the trial area
for at least 18 months, and currently at 17–24 com-
pleted weeks of gestation (i.e., 17 weeks + 0 days to 24
weeks + 0 days, inclusive) based on recalled last men-
strual period (LMP) and ultrasound performed by
MCHTI technicians (Just Vision 400, Toshiba, Tokyo,
Japan; SonoAce X8, Samsung Medison, South Korea). All
potential participants undergo routine ultrasound. If there
is a difference of more than 10 days between gestational
age (GA) calculated using the recalled LMP and second-
trimester ultrasound, the estimated date of delivery is ad-
justed as per the second-trimester ultrasound. Otherwise,
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the GA date based on recalled LMP is used [36]. If more
than one ultrasound report is available, GA estimation is
based on the earliest of the ultrasounds. If the earliest
ultrasound was performed in the first trimester and there
is a difference of more than 5 days between GA calculated
using the recalled LMP and first-trimester ultrasound, the
estimated date of delivery is adjusted as per the first-
trimester ultrasound [36].
Pregnant women are not enrolled if any of the follow-
ing exclusion criteria apply: self-reported history of any
medical condition or medications that may predispose
to vitamin D sensitivity, altered vitamin D metabolism,
and/or hypercalcemia (e.g., active tuberculosis or
current therapy for tuberculosis, sarcoidosis, history of
renal and/or ureteral stones, parathyroid disease, renal
or liver failure, or current use of antiseizure medica-
tions); high-risk pregnancy based on point-of-care
(POC) testing (hemoglobin [Hb] <70 g/L; proteinuria,
defined as ≥300 mg/dl based on urine dipstick; hyper-
tension, defined as systolic blood pressure ≥140 mmHg
and/or diastolic blood pressure ≥90 mmHg); high-risk
pregnancy based on maternal report and/or past ultra-
sound findings (multiple gestation, major congenital
anomaly, severe oligohydramnios); unwillingness to stop
taking non-study vitamin D or calcium supplements or a
multivitamins containing calcium and/or vitamin D; cur-
rently prescribed vitamin D supplements as part of a phy-
sician’s treatment plan for vitamin D deficiency; and/or
previous enrollment in the MDIG trial during a prior
pregnancy.
All participants provide written informed consent be-
fore randomization. The informed consent process is
undertaken in conjunction with the iterative eligibility
assessment: preliminary screening (based on age, loca-
tion of residence, plans to remain in referral area), de-
tailed medical screening by a study physician, POC
testing (blood pressure, urine dip, Hb), and obstetric
ultrasound. Women may choose to exit the enrollment
process at any time. Among prospective participants
who complete the screening process and are found to
meet all criteria, a detailed discussion of the trial is
undertaken before written informed consent is sought.
Eligible pregnant women are encouraged to discuss trial
participation with their spouse and/or other family
members before finalizing consent. Two additional con-
sent procedures are undertaken at a later time for sup-
plemental study procedures: (1) husbands of enrolled
participants are approached to obtain consent for pater-
nal anthropometry and blood specimen collection, and
(2) enrolled participants are approached at or beyond 30
weeks of gestation to request the participation of their
infant in an ARI substudy during the 0- to 6-month
postnatal period (detailed methods of the ARI substudy
will be presented elsewhere).
Design and sample size
The MDIG trial is a randomized, placebo-controlled,
double-blinded, dose-ranging trial with a 1:1 allocation
ratio across five parallel groups (Fig. 1). A total of 1300
pregnant women will be randomized, with a target of al-
locating 260 women in each group (Fig. 1). The primary
outcome analysis will be a between-group comparison of
mean LAZs at 1 year of age, assuming up to 15 % attri-
tion from each group before this time point. To assess
the effect of prenatal vitamin D, we plan to perform five
primary between-group analyses, comprising each vita-
min D dose versus placebo (three comparisons) and
comparisons between adjacent doses (two comparisons).
A conservative approach to addressing multiple testing
is to partition the α (risk of type I error) among the five
comparisons (conventional overall 0.05 divided by 5);
thus, each between-group comparison will be tested as a
two-sided test with an α of 0.01, assuming 90 % power.
With 220 analyzable participants per group (about 85 %
of total enrolled), the minimum detectable difference in
LAZ will be 0.40 z-score units, which equates to ap-
proximately 1.0 cm at 1 year of age based on WHO
growth standards. In our preliminary trial, we observed
an increase in LAZ of 0.44 at 1 year attributable to pre-
natal vitamin D supplementation, which corresponded
to an increase of 1.1 cm (95 % CI, 0.06–2.0), adjusted for
sex [26].
The secondary analysis at 2 years of age will enable de-
tection of an approximately 1.2-cm difference between
groups. For the postpartum effect analysis of 28,000 IU/
wk versus placebo postpartum among women who re-
ceived 28,000 IU/wk antenatally, the comparison at 1
year of age will have a minimum detectable difference of
0.31 z-score units (assuming 90 % power, a 5 % risk of a
type I error for a two-sided test, and at least 220 partici-
pants per group). Based on WHO growth standards, this
is approximately 0.77 cm at 1 year of age and 0.96 cm at
2 years of age. Because the α is not subject to multiple
testing for the postpartum effect analysis, there is greater
precision to detect a smaller difference compared with
the prenatal effect analysis. In order to enroll 1300 par-
ticipants, we expect to provisionally screen approxi-
mately 15,000 pregnant women for eligibility. The major
reasons for exclusion during preliminary screening are
GA beyond 24 weeks and residence outside the study
area.
Randomization and allocation concealment
The allocation sequence was generated by the trial stat-
istician (ARW) using a computer-generated random
number sequence according to a simple randomization
scheme (i.e., no stratification or blocking) [37]. The list
was provided to the Toronto Institute for Pharmaceut-
ical Technology (TIPT), the pharmaceutical company
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that has produced and packaged the supplements in in-
dividual participant supplement packs, each of which is
labeled with a unique participant identifier. The prela-
beled supplement packets containing both prenatal and
postpartum supplements (in separate vials) are sequen-
tially allocated to participants according to their order of
enrollment. Participants, investigators, field personnel,
study laboratory staff, and data analysts are blinded to
vitamin D or placebo group allocation. The allocation
scheme will be made available to the Data and Safety
Monitoring Board (DSMB) in cases in which individual
participants need to be unmasked because of suspected
supplement-related adverse events (i.e., hypercalcemia or
clinical features suggestive of vitamin D toxicity).
Interventions and control
Vitamin D doses
The primary objective of the MDIG trial is to establish
evidence of a causal relationship between maternal-infant
vitamin D status and infant stature. A randomized dose-
ranging trial enables robust causal inferences based on
dose–response effects, in addition to relatively unbiased
comparisons with the placebo group. Three vitamin D3
doses (4200 IU/wk, 16,800 IU/wk, and 28,000 IU/wk)
were selected on the basis of preliminary data, published
literature, and consideration of the 2010 IOM dietary ref-
erence intakes [38] (see Additional file 1 for detailed ra-
tionale). Pharmacological principles and empirical data
indicate that weekly doses of vitamin D achieve 25(OH)D
Fig. 1 Maternal Vitamin D for Infant Growth (MDIG) trial flow diagram. The allocated intervention in each group is shown as “prenatal
intervention; postpartum intervention”
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levels similar to equivalent daily doses [39]; thus, the
equivalent daily doses in increasing order are 600 IU/day,
2400 IU/day, and 4000 IU/day. Our previous pharmacoki-
netic findings among pregnant women in Dhaka [16, 40]
have generally been consistent with published estimates of
the vitamin D-to-25(OH)D dose–response relationship in
non-pregnant adults (i.e., an approximately 0.7 nmol/L in-
crease in 25(OH)D at steady state for each 1 μg/day of
vitamin D3 [41, 42]). The preliminary pharmacokinetic
studies have provided evidence of the biochemical efficacy,
tolerability, and short-term safety of doses of up to 35,000
IU/wk in pregnancy in the target population. Hollis et al.
previously reported that doses up to 4000 IU/day were
well tolerated and efficacious at raising 25(OH)D in preg-
nant women in the United States [43].
Study tablets
Oral vitamin D3 (cholecalciferol) is provided as small
tablets (10 mm diameter) that are custom-manufactured
by TIPT in Toronto, ON, Canada (www.tipt.com). Each
participant’s weekly dose consists of a single tablet.
Across trial groups, the tablets vary only by the vitamin
D3 dose but are identical with respect to appearance,
taste and excipients (Table 1). Vitamin D3 content per
tablet has been verified in each production batch
(Table 2), with a very high degree of tablet uniformity (F.
Martinuzzi, personal communication, December 2014).
Supplement administration
Supplementation begins at enrollment (second trimes-
ter) and continues on a weekly basis throughout preg-
nancy and the postpartum period until 26 weeks
postpartum (6 months). Study personnel maintain and
store all tablet supplies in locked study offices and dir-
ectly observe tablet ingestion during home or clinic
visits. However, for periods of up to 4 weeks during
which the participant plans to travel or during holidays,
advance doses may be given to the participant to take
unobserved but with telephone reminders. Tablets are
swallowed whole with any liquid (e.g., water, juice, tea)
or, if necessary, chewed with or without a small amount
of soft food. Tablets may be consumed with or without
food, which has a negligible impact on vitamin D ab-
sorption [44]. Although scheduled for specific 7-day in-
tervals, a missed dose may be administered as a late
dose on any day up to 7 days after the scheduled date of
administration; thereafter, subsequent dosing continues
as originally scheduled, even if this incurs at an interval
of less than 7 days between the late dose and the subse-
quent regularly scheduled dose. If a participant refuses a
dose or complains of feeling unwell (e.g., nausea) on the
scheduled day of dose administration, the dose may be
deferred for up to 7 days. If a participant vomits during
or within 20 minutes of dose administration (observed
by study personnel), the dose may be repeated immedi-
ately or may be deferred to another day (within 7 days).
If vomiting occurs more than 20 minutes after a dose
was swallowed, the dose is considered successfully ad-
ministered. If a participant refuses doses for 3 consecu-
tive weeks and in the third week expresses the intention
to continue avoidance and/or refusal of the dose, weekly
supplementation may be discontinued, but clinical
follow-up and scheduled data collection procedures may
continue.
Micronutrient cointerventions
Calcium 500 mg/day as calcium carbonate (Calbo; Square
Pharmaceuticals, Dhaka, Bangladesh) and iron and folic
acid (66 mg elemental iron per day, and 350 μg folic acid
per day included in the standard formulation available in
Bangladesh) are provided to all participants throughout
the intervention phase (prenatal period and up to 6
months postpartum). Although prenatal calcium supple-
mentation is not formally recommended or widely prac-
ticed in Bangladesh, standard provision of calcium was
incorporated into the trial design to mitigate any rate-
limiting effects of serious maternal dietary calcium deficits
on fetal growth or other outcomes. From a practical
standpoint, the investigation of vitamin D supplementa-
tion in the context of routine calcium supplementation
will facilitate the translation of trial findings into antici-
pated future contexts in which supplemental calcium is
Table 1 Vitamin D3 and excipient content of custom-made
tablets for the Maternal Vitamin D for Infant Growth triala














aComposition information provided by the manufacturer (Toronto Institute of
Pharmaceutical Technology, Toronto, ON, Canada)
bPlacebo granules were identical except for the absence of vitamin D3
cDry vitamin D3 100 GFP/HP (BASF, Mississauga, ON, Canada)
dα-Tocopherol is included as an antioxidant to stabilize the vitamin D3. The
vitamin E content of each tablet is 2.8 mg/wk (about 0.4 mg/day), which is far
below recommended dietary allowances for pregnancy (15 mg/day) and
lactation (19 mg/day)
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more routinely provided. We considered the recent rec-
ommendation by the WHO advising 1.5–2 g/day of sup-
plemental calcium for pregnant women with low dietary
calcium intake [45], but this policy has not been widely
adopted, owing to substantial logistical and technical limi-
tations. Supplemental calcium and/or vitamin D not pre-
scribed by the study protocol are prohibited during the
intervention phase of the trial. Participants are questioned
on a weekly basis as to whether they have consumed other
nutrient supplements. Participants who continue to con-
sume non-study supplements after an initial warning are
no longer permitted to continue receiving the allocated
intervention, although clinical follow-up and scheduled
data collection procedures may continue.
Visit schedule
Following enrollment and randomization of pregnant
women at 17–24 weeks of gestation, weekly supplemen-
tation (vitamin D or placebo) occurs throughout the pre-
natal period and during the first 6 months postpartum.
Data collection continues during the non-intervention
phase beginning at 26 weeks postpartum. The primary
anthropometric outcome will be ascertained at 1 year of
age, and follow-up of infants will continue until 2 years
of age. The prenatal timeline of study activities is struc-
tured in terms of GA (in weeks), based on the recalled
LMP and/or ultrasound results. Postnatal follow-up visits
are scheduled on the basis of the infant’s age in weeks (ra-
ther than anniversaries of the birthdate); however, the tim-
ing of major visits is operationally described in terms of
months or years for simplicity (e.g., 3 months = 13 weeks,
6 months = 26 weeks, 9 months = 39 weeks, 1 year = 12
months = 52 weeks, and 2 years = 24 months = 104
weeks).
Participant visits are scheduled on a weekly basis dur-
ing the prenatal and 6-month postpartum intervention
phase. The majority of visits are conducted in the partic-
ipants’ homes; however, selected visits that involve
specimen collection or anthropometry are preferentially
conducted in a clinic at MCHTI. Participants are
strongly encouraged to seek a facility-based delivery at
MCHTI; however, perinatal data and specimen collec-
tion are attempted when feasible for home deliveries or
for deliveries that occur at facilities other than MCHTI.
Beyond 6 months, clinic-based visits occur at 3-month
intervals until 2 years of age (Additional file 2). Partici-
pant retention is promoted through frequent interaction
between field-level study personnel and the participants
(weekly during the intervention phase). Adherence to
the schedule of clinic visits is facilitated by compensa-
tion of participants for costs of transportation and time
away from the home and/or work.
All study activities (e.g., supplementation, visits, mater-
nal and infant specimen collection) cease for a mother-
infant pair when any one of the following events occurs:
(1) the 24-month infant visit is completed, (2) partici-
pant (maternal) death before delivery, (3) stillbirth or in-
fant/child death, (4) consent for all types of follow-up is
withdrawn, or (5) loss to follow-up. Loss to follow-up is
considered to have occurred if (1) study staff determine
conclusively that the participant cannot be contacted for
the purposes of data collection for the duration of the
period of scheduled follow-up (e.g., they have been in-
formed of the participant’s emigration from Bangladesh)
or (2) at least 3 months have passed since the scheduled
but missed 24-month postnatal visit. A participant may
be absent for a period of time (and thus miss supple-
ment dosing, specimen collection, and other data collec-
tion) and yet return to follow-up without being excluded
from the study.
Data collection procedures
Trained personnel collect participant data using ques-
tionnaires, POC clinical tests, abstraction of prenatal
ultrasound reports, anthropometric measurements, and
specimen collection throughout the interventional and
observational phases of the study (Additional file 2). Data
are recorded using a series of standardized data collection
forms that are customized for each visit type. To over-
come low literacy in the population, field personnel ad-
minister all questionnaires as structured oral interviews. A
wide range of lifestyle and health-related items (e.g., ob-
stetric history, tobacco use, sun exposure) are included in
baseline and follow-up questionnaires. Dietary intake of
vitamin D, calcium, phosphorus, and phytates are assessed
among participants (mothers) at enrollment and 6 months
postpartum using a customized, focused food frequency
questionnaire. Infant dietary patterns are assessed at
weekly visits to assess breastfeeding patterns and timing
of introduction and frequency of consumption of specific
complementary foods. A household survey to assess socio-
economic status is conducted at the first scheduled home
Table 2 Vitamin D3 content of custom-made trial tablets, based











4200 IU 106 % 103 % 101 %
16,800 IU 105 % 101 % 102 %
28,000 IU 102 % 101 % 99 %
aModified United States Pharmacopeia method, as reported by the
manufacturer (Toronto Institute of Pharmaceutical Technology, Toronto, ON,
Canada). Results shown reflect the batches completed and assayed at the time
of manuscript preparation, not the full set of batches to be used in the trial.
bSimilar results obtained in testing by independent third-party laboratory
(Alpha Laboratories, Toronto, ON, Canada)
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visit 1 week after enrollment, at the 9-month home post-
natal visit, and at the 21-month postnatal home visit.
POC tests include blood pressure measurement, urine
dipstick testing, and Hb concentration estimation. Ma-
ternal systolic and diastolic blood pressure is measured
using an automated digital blood pressure monitor
(WatchBP Home; MicroLife USA, Clearwater, FL, USA).
Two readings are taken at least 1 minute apart and re-
corded; if either diastolic or systolic measurements differ
between the paired readings by more than 10 mmHg, a
third measurement will be performed. For analysis,
paired readings will be averaged; where a third reading
has been obtained, the single discordant reading will be
excluded. Urine dipsticks (Urinalysis Reagent Test Strips;
Siemens Diagnostics, Erlangen, Germany) are used at
enrollment as part of the eligibility assessment and then
after enrollment if high blood pressure is detected (sys-
tolic blood pressure ≥140 mmHg and/or diastolic blood
pressure ≥90 mmHg) or if there are symptoms (e.g., dys-
uria) suggestive of urinary tract infection (to test for
leukocyte esterase). Maternal Hb will be measured at en-
rollment (as part of the eligibility screening process) in a
finger-stick blood sample using a handheld hemoglobin-
ometer (Hb 201; HemoCue, Ängelholm, Sweden). Infant
Hb is measured using the same HemoCue device at 6
months of age.
Standardized procedures for infant length, weight, and
head circumference (HC) measurements were adapted
from the INTERGROWTH-21st study standard operat-
ing procedures [46]. Other published resources were
adapted to develop standard protocols for measurement
of upper arm length (UAL) [47], mid-upper arm circum-
ference (MUAC) [48], and rump-to-knee length (RKL)
[49]. Infants are measured independently by two study
personnel at each visit. The paired measurements are
compared, and if they differ by more than the threshold
values (7 mm for length; 5 mm for HC, UAL, MUAC,
and RKL; and 50 g for weight), a second set of measure-
ments is performed. If the second pair of measurements
differs by more than the threshold values, the procedure
is repeated a third time (except for infant weight, which
is measured using a digital scale and thus expected to be
concordant). Length, weight, and HC are measured at
birth, at one randomly assigned weekly visit during the
first 2 months after birth, and then every 3 months start-
ing at the 3-month visit. MUAC, UAL, and RKL are
measured at 3, 6, 12, and 24 months; UAL and RKL are
also measured at birth.
Length, HC, MUAC, UAL, and RKL are recorded to
the last completed unit. For each infant at each time
point, the mean of acceptable paired measures will be
used in primary analyses. Infant weight is measured to
the nearest 5 g (up to 10 kg) and to the nearest 10 g (for
>10 kg) using a digital infant scale (seca 334; Seca,
Hamburg, Germany). Length is measured to the last
completed 0.1 cm (1 mm) using a wooden length board
(Infant/Child ShorrBoard; Weigh and Measure, Olney,
MD, USA). Initially, we selected a length board with a
counter display and a ball bearing mounted sliding foot-
board (Harpenden infantometer; Holtain, Crymych, UK),
but decalibration of the counter occurred frequently,
particularly when the instrument was moved among as-
sessment locations. Therefore, as of 15 December 2014,
the ShorrBoard was adopted because of its easier port-
ability and robustness. HC, MUAC, and UAL are
measured using a flexible tape measure, and RKL is
measured using a rigid caliper (Holtain-Kahn Abdominal
Caliper; Holtain). These dimensions are measured to the
last completed 0.1 cm (1 mm). An anthropometric
standardization workshop was conducted before launch
of anthropometric data collection, which was adapted
from the methods of the WHO [50] and the
INTERGROWTH-21st study group [51].
Maternal and paternal weight and height are measured
at MCHTI according to standard methods adapted from
the National Health and Nutrition Examination Survey
Anthropometry Procedures Manual of the Centers for
Disease Control and Prevention [47], using a digital floor
scale (HD-318; Tanita, Tokyo, Japan) and a stadiometer
(Leicester Height Measure device; Chasmors, London,
UK). Measurements are performed in duplicate. Third
measurements are taken if the following discrepancies
are noted between the paired measures: more than 0.5
kg for weight and more than 2 cm for height.
Specimen collection
Blood specimen collection
Trained phlebotomists collect maternal blood, paternal
blood, cord venous and arterial blood, and infant blood
specimens according to standard sampling procedures
(Table 3). Following filling, BD Vacutainer serum (red
top) and ethylenediaminetetraacetic acid (EDTA) (laven-
der or blue top) blood collection tubes (BD Diagnostics,
Franklin Lakes, NJ, USA) are inverted according to the
manufacturer’s instructions and centrifuged immediately
(EDTA) or after 30 minutes (serum) at low speed for 15
minutes, and the supernatant (plasma or serum) is trans-
ferred via micropipettes in 0.25-ml aliquots into prela-
beled microfuge tubes (Fisherbrand Free-Standing
Microcentrifuge Tubes with Screw Caps; Thermo Fisher
Scientific, Waltham, MA, USA). Whole blood aliquots
(1.5 or 0.5 ml, depending on size of blood draw and la-
boratory requirements) are drawn from EDTA tubes im-
mediately after mixing (before centrifugation) for paternal
blood, maternal blood at delivery, and cord venous blood
specimens. Within 30 minutes of blood collection, serum
and plasma aliquots are placed in a portable ultracold
freezer (Shuttle ULT-25N; Stirling Ultracold, Athens, OH,
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USA) and maintained at less than −70 °C. At the comple-
tion of each workday, frozen aliquots are transported in
the portable freezer or a liquid nitrogen canister to an up-
right −80 °C freezer maintained with backup generator
support and constant monitoring. One serum aliquot
from each maternal and infant 3- and 6-month blood spe-
cimen is reserved at 2–8 °C for same- or next-day serum
calcium measurement.
Cord blood collection
The technique and timing of umbilical cord clamping
and cutting is determined by the attending physician or
birthing attendant (i.e., cord clamping time is not set by
the study protocol, but is recorded). As soon as possible
within 30 minutes of delivery of the placenta, a site on
the umbilical cord attached to the placenta is cleansed
using dry cotton gauze to wipe away any maternal blood.
The umbilical vein is cannulated, and blood is collected
into collection tubes in the following order: (1) serum
(red top) tube, (2) EDTA (lavender top) tube, and (3) trace
element (blue top) tube with EDTA. Any remaining
extractable blood is collected in EDTA (lavender top)
tubes. Attempts are made to collect a total of 20–40 ml of
cord blood. If feasible, the umbilical artery is cannulated
and a serum (red top) tube also filled.
Placental weight and specimen collection
After collection of cord blood, the umbilical cord and
membranes are removed from the placenta; the blood is
drained; and the placenta is weighed to the nearest 0.5 g
(iBALANCE i2500; My Weigh Canada, Vancouver, BC,
Canada). Placental specimens from at least two quad-
rants of the placenta are collected and divided into three
specimen types: (1) full disc biopsies of approximately
0.5-cm thickness that are stored in 10 % formalin at
room temperature for histopathological examination; (2)
small tissue samples (approximately 0.2 cm3) from the
fetal surface of the placenta that are stored in RNA Save
(Biological Industries Israel Beit Haemek, Kibbutz Beit
Haemek, Israel) at 2–8 °C for 48 h and then transferred
to −80 °C until epigenetic and/or gene expression stud-
ies are done; and (3) small tissue samples (about 0.2
Table 3 Biological specimen collection schedule and planned laboratory analyses in the Maternal Vitamin D for Infant Growth






















25(OH)D R S S S S S
1,25(OH)2D, whole/bioactive PTH(1–84),
C-terminal PTH(73–84), intact PTH, FGF-23
S S S S S
PTHrP S S S S S S S
IGF-1, IGFBP-1, IGFBP-3 S S
Ferritin S
Retinol, folate, cadmium S
C-reactive protein, IL-6, IL-8, TNF-α S S
Epigenetic studies S S S
Collection for future analyses R R R R R R R R R R
Placenta Epigenetic studies R
Urine Calcium:creatinine ratio R S
Calcium, phosphate, fluoride, cyclic AMP S
Collection for future analyses R R R
Breast milk PTHrP S S
Collection for future analyses R R
Nasal swabb PCR for respiratory viruses Rb Rb
PCR for Streptococcus carriage density Rb Rb
FGF fibroblast growth factor, IGF insulin-like growth factor, IGFBP insulin-like growth factor-binding protein, IL interleukin; PTHrP parathyroid hormone–related
protein, R routine, S subset, TNF tumor necrosis factor
aRoutine analyses to be performed in all specimens collected; subset analyses to be performed in a sub-set of stored specimen aliquots
bNasal swabbing is performed at any time from 1 wk to 6 mo of age if criteria for acute respiratory infection are met
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cm3) from the maternal surface of the placenta that are
stored and used similarly to the specimens from the fetal
surface. Specimens from each quadrant are collected
and pooled to create aliquots that represent the entire
placental disc (one pooled histopathology sample and
multiple pooled RNA Save samples from each of the
fetal and maternal sides).
Urine and breast milk specimen collection
Maternal urine samples are self-collected into sterile
plastic containers at baseline after enrollment (but be-
fore first supplement dose), during labor before delivery,
and at the 6-month postpartum visit. For each sample,
1.5-ml aliquots are stored at −80 °C for future analyses.
In addition, an aliquot from the intrapartum sample is
held at 2–8 °C for same- or next-day analysis of the cal-
cium:creatinine (Ca:Cr) ratio (see below). Infant urine
samples are collected at the 6-month postnatal visit
using infant urine collection bags that adhere to the
perineum; 1.5-ml aliquots are stored at −80 °C for future
analyses. At 3 and 6 months postpartum, hand-expressed
midfeed breast milk samples are collected and stored
at −80 °C for future analyses. Between birth and 6 months
of age, midturbinate nasal swabs for viral PCR will be col-
lected from infants who meet clinical criteria for upper or
lower respiratory tract infections. (Detailed methods for
the ARI substudy will be presented elsewhere.)
Laboratory analyses
Vitamin D status is based on the serum 25(OH)D con-
centration [52] assessed by high-performance liquid
chromatography tandem mass spectrometry performed
at the Analytical Facility for Bioactive Molecules (Hos-
pital for Sick Children, Toronto, ON, Canada). This
assay captures 25(OH)D2 and 25(OH)D3, and enables
separate quantification of the C3-epi-25(OH)D moiety.
The current approach uses an Agilent 1290 Infinity
high-performance liquid chromatography system (Agi-
lent Technologies, Mississauga, ON, Canada) interfaced
with an AB Sciex QTRAP 5500 mass spectrometer
(SCIEX, Concord, ON, Canada), and separation by a
Kinetex 2.6-μm pentafluorophenyl 100mm×2.1mm col-
umn (Phenomenex, Torrance, CA, USA); however, itera-
tive improvements to the assay system will ensure it
remains state-of-the-art throughout the trial. In current
use, average intraassay percent coefficient of variation
(CV%) is 4 % and average interassay CV% is 6 %. Exter-
nal quality control mechanisms include participation in
the Vitamin D External Quality Assessment Scheme
(DEQAS, http://www.deqas.org/; London, UK) and use
of the National Institute of Standards and Technology
(Gaithersburg, MD, USA) standard reference material.
Serum calcium is measured by colorimetric measure-
ment of calcium–Arsenazo complex (Olympus-Beckman
Coulter autoanalyzer system; Beckman Coulter, Brea,
CA, USA) in the clinical biochemistry laboratory at
ICDDR,B (Dhaka, Bangladesh). Maternal and infant
serum calcium is routinely monitored in all participants
throughout the intervention phase of the trial (Table 3).
To address specific mechanistic hypotheses, several
other biochemical analytes will be measured in serum or
plasma aliquots and urine samples from a subset of par-
ticipants (Table 3). Details of these substudies will be de-
scribed elsewhere. For epigenetic studies, DNA and
mRNA will be extracted from blood and placental speci-
mens using techniques previously described [53]. Gen-
omic DNA will be subjected to bisulfite modification,
and amplified PCR products will be analyzed by quanti-
tative pyrosequencing to assess DNA methylation at
several consecutive CpG sites within an approximately
150-bp region at the promoters of two genes involved in
vitamin D metabolism (CYP27B1 and CYP24A1). Where
possible, paternal whole blood specimens will be col-
lected to enable the identification of allele-specific
patterns. Gene expression (mRNA) from placental speci-
mens (fetal tissue) will be assessed by real-time PCR.
Epigenetic analyses will be performed at the Weksberg
laboratory at the Hospital for Sick Children (Toronto,
ON, Canada). Molecular microbiological analyses of
nasal specimens will be performed at the virology and
microbiology laboratories at ICDDR,B. (Details of the
ARI substudy will be described elsewhere.)
Data management
A site supervisor reviews all data collection forms for
completeness and protocol deviations and/or violations
before sending them to the data management center at
ICDDR,B on a weekly basis. Electronic (scanned) ver-
sions of all forms are also regularly saved for long-term
storage. The database was designed using SQL Server
2008 and data are entered using Visual Studio 2010
(both from Microsoft, Redmond, WA, USA). A set of
range and consistency checks are built into the data cap-
ture system to provide immediate feedback to data entry
personnel regarding errors or inconsistent data. Double
data entry is used to further reduce the rate of date entry
errors.
Outcome measures
The primary trial outcome measure is LAZ at 1 year of
age, where length refers to an infant’s fully extended
crown-to-heel distance in the supine position. Growth
faltering in resource-poor settings primarily occurs early
[7], and any effects of the intervention are expected to
be apparent by 1 year of age. Our preliminary trial data
revealed a discernible effect of prenatal vitamin D sup-
plementation on infant LAZ at 1 year [26]. Because
some infants might not be reached at exactly 1 year of
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age (52 weeks), measurements taken up to 60 weeks will
be included in the primary 1-year outcome analysis, im-
plying a range of 364–420 days. LAZ based on WHO
growth standards will be used to account for sex imbal-
ances between groups and variance in exact age at the
time of measurement. Infant follow-up will continue to
2 years of age (with continued treatment masking) to es-
tablish the persistence of effects, to capture potential
catch-up growth, and because stunting prevalence does
not stabilize until 18–24 months of age [7]. To improve
uniformity with respect to the timing of the 2-year visit,
it will be scheduled at 24 months of age (104 weeks) but
may be completed up to 27 months of age.
LAZs and z-scores for weight for age (WAZ), weight
for length (WFLZ), and head circumference for age
(HCAZ) will be calculated according to the sex-specific
WHO growth standards (WHO-GS) [54, 55] using the
STATA igrowup package (http://www.who.int/child-
growth/software/en/). Extreme z-scores will be flagged by
the WHO Anthro software (less than −6 SD or greater
than 6 SD for LAZ, greater than 5 or less than −6 for
WAZ, greater than 5 or less than −5 for HCAZ, and
greater than −5 or less than 5 for WFLZ). These extreme
values will be manually reviewed to ensure they are not
the result of data recording or entry errors. Real values
that are extreme low outlying z-scores are expected to be
contributed primarily by infants who had early preterm
births and of very low birth weight. Other secondary
growth outcomes (UAL, MUAC, and RKL) and postnatal
growth velocity will be analyzed using raw values or age-
and sex-standardized z-scores based on WHO standards
(except for RKL).
Statistical analysis
For the primary trial efficacy outcome analysis, mean
LAZ (at 1 year of age) will be compared across groups
using analysis of variance. To assess the effect of pre-
natal vitamin D on mean LAZ at 1 year of age, we plan
to perform five primary between-group analyses: each
prenatal vitamin D dose versus placebo (three pairwise
comparisons), as well as comparisons between all adja-
cent vitamin D doses (two pairwise comparisons).
Because the primary hypotheses relate to differences be-
tween two groups, each analysis will be akin to an
independent-samples t test. The primary effect measure
for each comparison will be expressed as a mean differ-
ence between groups with 95 % CI. However, an overall
α for statistical significance for all five comparisons will
be 0.05 (two-sided), and the Holm test will be used to
account for multiple testing. Therefore, even if the 95 %
CI for a particular mean difference does not include
zero, it is possible that it may not be considered statisti-
cally significant when all five comparisons are presented
together. The postpartum effect analysis will be the
comparison of mean LAZ at 1 year of age between in-
fants of mothers who received 28,000 IU/wk versus pla-
cebo in the postpartum period (among women who
received 28,000 IU/wk prenatally), using a statistical ap-
proach similar to that described for the prenatal effect
analysis. The nominal αfor statistical significance will be
0.05 (two-sided test) for this analysis. Because there is
only one primary pairwise comparison related to the
postpartum effect, no adjustment for the multiplicity of
outcomes is planned.
In the primary analyses, an intention-to-treat (ITT)
approach will be used, meaning participants will be con-
sidered exactly as randomized, regardless of supplemen-
tation adherence or completeness of follow-up and
without adjustment for baseline covariates, and also
without imputation for missing data; that is, infants for
whom LAZ is unavailable at 1 year of age will be ex-
cluded from the analysis. However, because the trial is
aimed at establishing a biological mechanism of effect,
per-protocol analyses will also be performed by restrict-
ing to participants who consumed at least 90 % of all
scheduled doses. Conventional ITT analyses of postnatal
growth outcomes typically disregard between-individual
variations in GA at birth; however, because the WHO-
GS was based on a full-term cohort [54], this may lead
to differential misclassification of preterm infants with
respect to LAZ if length is plotted on the growth chart
using the chronological age. Although we plan to follow
the convention in the primary analysis, we will perform
a sensitivity analysis in which LAZ will be assigned to
preterm infants using the age corrected for GA at birth
(rather than chronological age). Several other sensitivity
analyses are planned. Multivariable adjustment will be
used for covariates that substantially differ across groups
at baseline. A missingness analysis will be performed to
understand the pattern of missing data (in particular to
detect differential loss of data across groups), and multiple
imputation methods will be used in sensitivity analyses to
correct for these losses. Subgroup and interaction analyses
will be based on the following covariates: GA at birth, in-
fant sex, maternal baseline vitamin D status, maternal
height, and maternal supplement adherence.
Two secondary approaches will be used to examine
the effects of vitamin D on linear growth. Regression
spline models, with knots at the major scheduled
follow-up visit time points, will be used to analyze
changes in mean LAZ over discrete time intervals.
Interaction terms for time and group allocation will be
used to test between-group differences in the changes in
LAZ during discrete time intervals. As well, participants
will be classified as “stunted” if LAZ is less than −2, and
both cross-sectional and longitudinal comparisons will
be undertaken to assess the relative risk of stunting
across groups. In longitudinal analyses of LAZ or
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stunting described above, generalized estimating equa-
tions with robust variance estimation will be employed
to account for within-subject correlation of repeated
measures [56].
Summary measures (e.g., means, frequencies, propor-
tions, incidence rates) and effect estimates (i.e., regres-
sion coefficients) will be reported as point estimates and
95 % confidence intervals. In general, risk ratios with
corresponding CIs will be used to compare dichotomous
outcomes across trial groups (e.g., prevalence of SGA),
and differences in means will be used for between-group
comparisons of continuous variables. P values will be re-
ported to three decimal places, with P values less than
0.001 reported as less than 0.001. Statistical analyses will
be performed using the STATA software package (Stata-
Corp, College Station, TX, USA) with analyses of pri-
mary trial outcomes performed in a blinded fashion.
Plans of analysis to address secondary objectives will be
presented elsewhere.
Participant safety monitoring
Participant safety during the intervention phase is mon-
itored by study personnel based on (1) a checklist of
maternal symptoms that may indicate vitamin D tox-
icity or other medical concerns during weekly follow-
up visits, (2) passive and active monitoring for maternal
and infant clinical events, and (3) maternal serum cal-
cium measurement at scheduled intervals during the
intervention phase (baseline, 30 weeks of gestation, de-
livery, 3 months postpartum, and 6 months postpar-
tum). Secondary safety measures include infant serum
calcium measurement at 3 and 6 months of age and
maternal urinary calcium:creatinine at the time of
delivery.
Serum calcium is the best available biomarker of vita-
min D toxicity [57, 58]; therefore, hypercalcemia is the
primary biochemical safety outcome. Nonetheless, on
the basis of our own experience with doses equivalent to
up to 5000 IU/day (see above) and previously published
trials conducted in the United States using doses up to
4000 IU/day during pregnancy [43] and up to 6400 IU/
day during lactation [59], we do not anticipate any epi-
sodes of true hypercalcemia or other supplement-related
adverse events.
Possible hypercalcemia is defined as a single serum cal-
cium concentration above 2.60 mmol/L. This threshold
is based on a conservative upper limit of the normal
range that accommodates expected variation in serum
calcium throughout pregnancy [60], but it avoids the un-
necessary operational complexity of using a normal
range that varies by stage of gestation. Any participant
with possible hypercalcemia detected through scheduled
blood sampling (or at the time of a clinical serious ad-
verse event; e.g., hospitalization) will be asked to provide
a second sample within 24 h of the time that the study
physician receives a report of an abnormal value. Abnor-
mal serum calcium results will always be reported and
confirmed before the time of the following week’s sup-
plement dose (to enable a decision to be made about
withholding supplementation). Severe derangements in
serum calcium will be managed as urgently as possible,
including referral for hospitalization.
Confirmed hypercalcemia is defined as serum calcium
concentration above 2.60 mmol/L in two consecutive
specimens and will be considered the primary
supplement-related adverse event. The second, con-
firmatory specimen is required owing to the possibility
of a laboratory error, but clinical management will not
await the second assay if the participant is symptomatic.
If the repeat serum calcium is normal, then supplemen-
tation will continue and a further repeat serum calcium
will be measured 1 week after the first abnormal result
to confirm that it remains within the normal range. In
the unlikely event that a participant has confirmed hy-
percalcemia, study personnel will follow the clinical
course until normalization of serum calcium or 1 month
postpartum (whichever occurs later). Participants with
mild and asymptomatic hypercalcemia may not require
referral or treatment beyond the cessation of supple-
mentation and will continue to participate in study
follow-up. Participants with confirmed or suspected
moderate to severe hypercalcemia (serum Ca >2.80
mmol/L and/or symptomatic) will be assessed at a hos-
pital by a clinician with expertise in the treatment of
hypercalcemia.
In previous prenatal vitamin D supplementation trials
in Dhaka, we used regular monitoring of maternal urin-
ary Ca:Cr ratio as a screening measure for vitamin D
toxicity [16, 40]. However, this test is non-specific and
frequently led to the need for repeat testing that was
burdensome but uninformative; in no cases did an iso-
lated Ca:Cr ratio indicate vitamin D toxicity. Therefore,
regular urine Ca:Cr ratio assessment is not employed as
a primary clinical safety monitoring tool in the present
trial. However, we will measure urinary Ca:Cr ratio in
mothers at delivery as a screening test for hypercalciuria
rather than for overt vitamin D toxicity. Abnormal
values (Ca:Cr ratio >1 mmol/mmol) will prompt repeat
testing, and either of the following criteria will be con-
sidered a presumptive diagnosis of hypercalciuria: two
consecutive urine samples with Ca:Cr ratio above 1
mmol/mmol or one urine sample with Ca:Cr ratio above
1 mmol/mmol in the presence of persistent symptoms
suggestive of possible uro- and/or nephrolithiasis. Partic-
ipants with persistent symptoms of renal colic or hyper-
calciuria will be referred for renal ultrasound to assess
for the presence of urolithiasis or nephrolithiasis. Partici-
pants with uro- or nephrolithiasis will be referred for
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consideration by the DSMB for a decision regarding
unblinding and possible discontinuation of the study
supplement, which is to be decided on a case-by-case
basis. Biochemical evidence of hypercalciuria alone will
not trigger urgent DSMB review, but it will be reviewed
at regular intervals. However, participants with hypercal-
ciuria and an absence of stones will undergo repeat
urine Ca:Cr ratio assessment 1 month after initial diag-
nosis. If hypercalciuria is persistent, a repeat ultrasound
will be undertaken.
When caregivers permit scheduled infant blood sam-
pling, serum calcium will be routinely measured. The nor-
mal range of infant serum calcium is higher than in
adults, and normal values may be as high as 3.05 mmol/L
[61–66]. However, because there are few reference data
for infants specifically at 3 and 6 months, we have chosen
to use a more conservative threshold of greater than 2.80
mmol/L to define above-range infant values at the 3- and
6-month visits, which will prompt repeat assessment.
Clinical events will be monitored and documented by
study physicians, and serious adverse events will include
all deaths and hospitalizations (with the exception of ad-
missions to the hospital for uncomplicated vaginal or
cesarean delivery). The only clinical events that will rou-
tinely lead to discontinuation of study supplementation
are those adverse events that are ascertained to be
supplement-related or the diagnosis of a medical condition
that potentially or theoretically increases sensitivity to vita-
min D supplementation following clinical review by the
Trial Steering Committee (TSC): confirmed hypercalcemia
(see definition above), symptomatic vitamin D deficiency
diagnosed by a study physician or consultant physician
(e.g., osteomalacia), fetal or infant death, or onset of a med-
ical condition or initiation of a medication following enroll-
ment that may reasonably predispose to vitamin D
sensitivity, altered vitamin D metabolism, and/or hypercal-
cemia (e.g., tuberculosis or therapy for tuberculosis, sar-
coidosis, renal and/or ureteral stones, parathyroid disease,
renal or liver failure, or use of anticonvulsants). The occur-
rence of a serious adverse event, in of itself, will not auto-
matically lead to study supplementation cessation.
Research ethics committee/institutional review board
approval was obtained from the Hospital for Sick Chil-
dren Research Ethics Board (REB1000039072) and the
ICDDR,B Ethical Review Committee (ERC; PR number
13055). A DSMB was created by the ERC of ICDDR,B.
An external international member of the TSC reviews
reports submitted to the DSMB and reports to the TSC.
There are no formal interim analyses of efficacy or stop-
ping rules planned for this trial.
Discussion
Since the publication of the 2010 IOM report on vitamin
D and the design of the MDIG trial and dosing regimens
in 2012, there have been several new reports of bio-
chemical and clinical findings of prenatal vitamin D sup-
plementation trials conducted in Iran [67–69], the
United Arab Emirates [70], Pakistan [71], New Zealand
[72], and Australia [73]. However, in none of these stud-
ies did researchers report postnatal infant growth out-
comes, and all trials enrolled fewer than 100 participants
per arm, suggesting they lacked power to detect effects
on most pregnancy-related and infant clinical outcomes.
The results of a relatively larger trial (N = 549) recently
completed in rural Pakistan (NCT01229189) have not
yet been released publicly. There are at least three other
large trials underway: the Maternal Vitamin D Osteopor-
osis Study, for which the primary outcome is neonatal
whole body bone mineral content [74]; the Vitamin D
Antenatal Asthma Reduction Trial [75]; and the Vitamin
D Supplementation during Pregnancy for Prevention of
Asthma in Childhood (ABCvitaminD trial; Clinical-
Trials.gov identifier NCT00856947). However, these and
other registered prenatal vitamin D trials are being con-
ducted in high-income countries.
The MDIG trial will therefore offer unique insights
into the effect of improving maternal-infant vitamin D
status in a low-income setting where vitamin D insuffi-
ciency is common and there is a high prevalence of in-
fant linear growth faltering. The trial is primarily
designed and powered to evaluate the dose–response ef-
fects of vitamin D on infant length, an outcome that is
directly aligned with the classical role of vitamin D in
mineral metabolism and bone health but may also be
interpreted as a surrogate marker for organ (including
brain) growth and development. Serial specimen collec-
tion and frequent clinical follow-up will enable a range
of secondary objectives to be addressed, including tests
of mechanistic hypotheses (e.g., mediation of the benefi-
cial vitamin D supplement effect on skeletal length by
PTH suppression) and assessments of the effects of the
intervention on infant morbidity (in particular, the inci-
dence of acute respiratory infections in the first 6
months after birth). Longer-term surveillance of the in-
fant cohort will ideally enable the assessment of other
important clinical outcomes (e.g., asthma, neurodevelop-
ment) that may be influenced by the non-classical role
of vitamin D in immunoregulation and extraskeletal cel-
lular proliferation and differentiation.
Trial status
As of July 2015, enrollment is ongoing.
Additional files
Additional file 1: Summary of the rationale for the maternal
prenatal and postpartum vitamin D3 doses selected for the trial.
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Additional file 2: Overview of study activities scheduled for each
participant enrolled in the trial.
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